Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp. develops enabling technologies and services for pharmaceutical, high-value chemical, and related laboratory markets. Company news commonly covers Self-Driving Laboratories, the DirectInject-LC™ automated sampling and analysis product, contract research services, customer installations, technology collaborations, and technical outreach to scientific and investor audiences.
Updates also address financial results, product fulfillment, hiring and operating expenses tied to growth, and Telescope's lithium processing portfolio, including DualPure™ and ReCRFT™ technologies for battery-material applications. The company's announcements connect automation, chemical process development, and materials R&D with recurring disclosures on revenue drivers, partnerships, and commercialization activity.
Telescope Innovations (OTCQB: TELIF) has rescoped its prior digital marketing agreement with Gold Standard Media, which refunded $300,000 in previously paid fees to the company. Telescope engaged Curzio Research Holdings for digital marketing and investor awareness services under a three-month agreement starting March 1, 2026, with an upfront payment of USD $300,000. Curzio and its CEO Frank Curzio are at arm's length and report no ownership in Telescope. Curzio is US-based and provided contact details for investor inquiries.
Telescope Innovations (OTCQB: TELIF) installed a second Self-Driving Laboratory (SDL) at Pfizer under a multi-year agreement; installation completed in January 2026.
The second Physical AI platform advances a move from collaborative R&D toward potential full-scale deployment, aiming to shorten development timelines and reduce chemistry research costs via AI-guided experimentation and robotic automation.
Telescope Innovations (OTCQB: TELIF) reported Q1 fiscal 2026 results for the quarter ended Nov 30, 2025: revenues CAD $2.70M (Q1 FY2025: $1.20M) and an adjusted EBITA loss CAD $0.83M (Q1 FY2025: loss $0.10M). Revenue growth was driven by DirectInject-LC product sales, Contract Research Services and delivery of the first Self Driving Laboratory to KPBMA.
Expenses rose as the company invested in hiring, parts, travel and professional services. Telescope closed a $6.50M capital raise and received conditional government funding of $3.60M for lithium recycling and solid-state battery work.
Telescope Innovations (OTCQB: TELIF) announced expansion of its lithium development infrastructure and technical validations for its proprietary processes on January 27, 2026. The company leased additional lab and scale-up space adjacent to its UBC labs to house reactors and analytical equipment for air-sensitive materials like lithium sulfide, with commissioning as a near-term priority.
Technical milestones include ReCRFT producing battery-grade Li2CO3 that was successfully used by a recycling partner to manufacture a functional battery cell, and DualPure demonstrating a low-temperature route to high-purity Li2S with development funded in part by Standard Lithium.
Telescope (OTCQB:TELIF) outlined a 2026 development pipeline to expand its DirectInject-LC platform into DirectInject-IC (ion chromatography) and DirectInject-ICP (inductively coupled plasma) to broaden real-time analytical capabilities for Self-Driving Labs. The company positions these integrations to enable autonomous, quantitative monitoring across inorganic chemistry, hydrometallurgy, lithium extraction, and energy & battery materials.
Early-adopter deployments and testing are targeted for H2 2026, aiming to extend commercial reach beyond organic chemistry into minerals and industrial process monitoring.
Telescope Innovations (OTCQB: TELIF) provided a strategic update on accelerating commercial adoption of Self-Driving Labs (SDLs) and the rise of Physical AI on January 5, 2026.
Key developments include a successful pharmaceutical SDL deployment for the KPBMA, a multi-year, funded SDL development project with Pfizer, and management saying FY 2025 delivered record sales performance. The release cites industry validation: Gartner named Physical AI a 2026 macro trend, Global X flagged an "Automation Age," and Grand View Research projects the global lab-automation market to reach US $18.39 billion by 2033 (CAGR 9.3%).
The company positions its SDL architecture as a scalable industrial asset for pharmaceuticals, industrial chemistry, agriculture & energy, and long-term space/off-Earth research.
Telescope Innovations (OTCQB: TELIF) authorized equity compensation and a shares-for-debt settlement on December 31, 2025. The company granted up to 250,000 stock options to a consultant at a strike of $0.33 exercisable until Dec 31, 2030 with a four-month-plus-one-day cliff and annual vesting thereafter. It also granted 192,000 RSUs to three directors valued at $48,000 under director fee arrangements with the same vesting schedule.
The CEO, Henry Dubina, agreed to settle $12,000 of fees via issuance of 48,000 common shares at a deemed price of $0.25 per share; those shares carry the statutory four-month hold. The company disclosed this as a related-party transaction and said it will rely on specified MI 61-101 exemptions.
Telescope Innovations (OTCQB: TELIF) reported fiscal 2025 results for the year ended August 31, 2025, with revenues of CAD $5.8M versus $4.4M in FY2024 and an Adjusted EBITDA loss of $402K (FY2024 loss $152K). Expenses rose to CAD $7.3M.
Operational milestones include a multi‑year funded Self‑Driving Lab (SDL) project with Pfizer, record quarterly sales for DirectInject‑LC and expansion into Europe and Asia, production and first sample shipments of battery‑grade lithium sulfide, and planned deployment of the first SDL for pharmaceutical development in Korea in FY2026.
Telescope Innovations (OTCQB: TELIF) completed installation of Korea's first pharmaceutical Self-Driving Lab (SDL) for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association on December 9, 2025. The SDL was deployed only three weeks after contract signing, demonstrating rapid delivery capability. The project included on-site participation by two-time Chemistry Nobel Prize winner Prof. Barry Sharpless and was enabled by collaboration with the Acceleration Consortium and Canadian–Korean partners. Telescope says the installation will accelerate R&D workflows via automated robotics, inline analytics, and AI, and positions the company to expand SDL adoption across pharmaceutical, industrial chemistry, energy, and agricultural sectors.
Telescope Innovations (OTCQB: TELIF) announced that Korea's Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has purchased a Self-Driving Lab (SDL) to be installed at a new R&D facility in Seoul within weeks (announcement dated November 17, 2025).
The SDL will form the core of KPBMA's first AI-driven training hub under the Convergence AI Institute for Drug Discovery (CAIID), supporting automation, education, and upskilling across KPBMA's 300 member companies. Telescope said the SDL uses robotics, inline analytics, and AI to run continuous closed-loop experiments that can accelerate iterative R&D and shorten development timelines. Telescope and KPBMA plan a strategic partnership to deploy and promote SDL adoption across Korea and the wider Asian market.